Drug Trial Radar · NCT05642546
First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers
Last checked: Nov 19, 2026Latest source record: Dec 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 12, 2020
Primary completion
Jun 15, 2022
Study completion Jun 15, 2022
Sponsor
- Lead sponsor
- NovelMed TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Labcorp Corporation of America Holdings, Inc
- First posted
- Dec 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1 randomized, double-blind, placebo-controlled, single administration, sequential cohort with sentinel dosing, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of NM8074 in healthy subjects. This study will include 5 cohorts, with each cohort consisting of a total of 8 healthy subjects, including both males and females, randomized in a 3:1 ratio of NM8074 to placebo (6 subjects assigned to NM8074 and 2 subjects assigned to placebo).
Conditions
- Healthy
Interventions
NM8074Drug
Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases
PlaceboDrug
Saline Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monitoring of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 71 days post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Unit
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.